ArticleBlood advances2026

Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.

Nastassja Scheidegger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.